Plasma zinc level and thymic hormone activity in young cancer patients

Eugenio Mocchegiani, Paolo Paolucci, Donatella Granchi, Laura Cavallazzi, Lory Santarelli, Nicola Fabris

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

It has been reported that in many neoplastic diseases, including leukemia, alterations in plasma zinc levels may frequently occur, although the causes for such alterations have yet to be clearly defined. Since zinc is required to induce biological activity to thymulin (Zn-FTS), a biochemical defined thymic hormone, and marginal zinc deficiencies may prevent its peripheral biological activation, we investigated the plasma level of zinc and of both active thymulin (Zn-FTS) and total zinc saturable thymulin (Zn-FTS + FTS) in 91 young patients affected by acute lymphoblastic leukemia (ALL) at various stages of the disease. It was discovered that the plasma zinc level was reduced at the onset and relapse, whereas in complete remission and in off- therapy it was in the normal range. Total zinc-saturable thymulin concentration did not change during the disease, whereas the active fraction was reduced at the onset and in relapse when compared with values observed in the other stages of the disease or in healthy controls. These data suggest that zinc plasma deficiency is present in ALL patients at the onset and during relapse, and that such a deficiency causes a decrease in the activity of thymulin despite a nearly normal production by the thymus. An impairment of peripheral immune efficiency in ALL patients is commonly found. The existence of positive correlations between zinc or active thymulin and peripheral immunological parameters (phytohemogglutinin [PHA] and concanavalin A [ConA]) at various stages of the disease suggests a link between derangement of peripheral immune function, thymic hormone activity, and zinc failure. These findings, considered together, suggest the possibility of a carefully controlled clinic trial with zinc in ALL patients at the onset and in relapse even in the light of in vitro ineffectiveness of physiological zinc or thymulin concentrations on the duplicative index of human lymphoblastoid cells.

Original languageEnglish
Pages (from-to)749-757
Number of pages9
JournalBlood
Volume83
Issue number3
Publication statusPublished - Feb 1 1994

Fingerprint

Thymus Hormones
Circulating Thymic Factor
Zinc
Plasmas
Neoplasms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recurrence
Thymus
Concanavalin A
Bioactivity
Thymus Gland

ASJC Scopus subject areas

  • Hematology

Cite this

Mocchegiani, E., Paolucci, P., Granchi, D., Cavallazzi, L., Santarelli, L., & Fabris, N. (1994). Plasma zinc level and thymic hormone activity in young cancer patients. Blood, 83(3), 749-757.

Plasma zinc level and thymic hormone activity in young cancer patients. / Mocchegiani, Eugenio; Paolucci, Paolo; Granchi, Donatella; Cavallazzi, Laura; Santarelli, Lory; Fabris, Nicola.

In: Blood, Vol. 83, No. 3, 01.02.1994, p. 749-757.

Research output: Contribution to journalArticle

Mocchegiani, E, Paolucci, P, Granchi, D, Cavallazzi, L, Santarelli, L & Fabris, N 1994, 'Plasma zinc level and thymic hormone activity in young cancer patients', Blood, vol. 83, no. 3, pp. 749-757.
Mocchegiani E, Paolucci P, Granchi D, Cavallazzi L, Santarelli L, Fabris N. Plasma zinc level and thymic hormone activity in young cancer patients. Blood. 1994 Feb 1;83(3):749-757.
Mocchegiani, Eugenio ; Paolucci, Paolo ; Granchi, Donatella ; Cavallazzi, Laura ; Santarelli, Lory ; Fabris, Nicola. / Plasma zinc level and thymic hormone activity in young cancer patients. In: Blood. 1994 ; Vol. 83, No. 3. pp. 749-757.
@article{1e15465eb8544e5d90dcc9facec6dc90,
title = "Plasma zinc level and thymic hormone activity in young cancer patients",
abstract = "It has been reported that in many neoplastic diseases, including leukemia, alterations in plasma zinc levels may frequently occur, although the causes for such alterations have yet to be clearly defined. Since zinc is required to induce biological activity to thymulin (Zn-FTS), a biochemical defined thymic hormone, and marginal zinc deficiencies may prevent its peripheral biological activation, we investigated the plasma level of zinc and of both active thymulin (Zn-FTS) and total zinc saturable thymulin (Zn-FTS + FTS) in 91 young patients affected by acute lymphoblastic leukemia (ALL) at various stages of the disease. It was discovered that the plasma zinc level was reduced at the onset and relapse, whereas in complete remission and in off- therapy it was in the normal range. Total zinc-saturable thymulin concentration did not change during the disease, whereas the active fraction was reduced at the onset and in relapse when compared with values observed in the other stages of the disease or in healthy controls. These data suggest that zinc plasma deficiency is present in ALL patients at the onset and during relapse, and that such a deficiency causes a decrease in the activity of thymulin despite a nearly normal production by the thymus. An impairment of peripheral immune efficiency in ALL patients is commonly found. The existence of positive correlations between zinc or active thymulin and peripheral immunological parameters (phytohemogglutinin [PHA] and concanavalin A [ConA]) at various stages of the disease suggests a link between derangement of peripheral immune function, thymic hormone activity, and zinc failure. These findings, considered together, suggest the possibility of a carefully controlled clinic trial with zinc in ALL patients at the onset and in relapse even in the light of in vitro ineffectiveness of physiological zinc or thymulin concentrations on the duplicative index of human lymphoblastoid cells.",
author = "Eugenio Mocchegiani and Paolo Paolucci and Donatella Granchi and Laura Cavallazzi and Lory Santarelli and Nicola Fabris",
year = "1994",
month = "2",
day = "1",
language = "English",
volume = "83",
pages = "749--757",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Plasma zinc level and thymic hormone activity in young cancer patients

AU - Mocchegiani, Eugenio

AU - Paolucci, Paolo

AU - Granchi, Donatella

AU - Cavallazzi, Laura

AU - Santarelli, Lory

AU - Fabris, Nicola

PY - 1994/2/1

Y1 - 1994/2/1

N2 - It has been reported that in many neoplastic diseases, including leukemia, alterations in plasma zinc levels may frequently occur, although the causes for such alterations have yet to be clearly defined. Since zinc is required to induce biological activity to thymulin (Zn-FTS), a biochemical defined thymic hormone, and marginal zinc deficiencies may prevent its peripheral biological activation, we investigated the plasma level of zinc and of both active thymulin (Zn-FTS) and total zinc saturable thymulin (Zn-FTS + FTS) in 91 young patients affected by acute lymphoblastic leukemia (ALL) at various stages of the disease. It was discovered that the plasma zinc level was reduced at the onset and relapse, whereas in complete remission and in off- therapy it was in the normal range. Total zinc-saturable thymulin concentration did not change during the disease, whereas the active fraction was reduced at the onset and in relapse when compared with values observed in the other stages of the disease or in healthy controls. These data suggest that zinc plasma deficiency is present in ALL patients at the onset and during relapse, and that such a deficiency causes a decrease in the activity of thymulin despite a nearly normal production by the thymus. An impairment of peripheral immune efficiency in ALL patients is commonly found. The existence of positive correlations between zinc or active thymulin and peripheral immunological parameters (phytohemogglutinin [PHA] and concanavalin A [ConA]) at various stages of the disease suggests a link between derangement of peripheral immune function, thymic hormone activity, and zinc failure. These findings, considered together, suggest the possibility of a carefully controlled clinic trial with zinc in ALL patients at the onset and in relapse even in the light of in vitro ineffectiveness of physiological zinc or thymulin concentrations on the duplicative index of human lymphoblastoid cells.

AB - It has been reported that in many neoplastic diseases, including leukemia, alterations in plasma zinc levels may frequently occur, although the causes for such alterations have yet to be clearly defined. Since zinc is required to induce biological activity to thymulin (Zn-FTS), a biochemical defined thymic hormone, and marginal zinc deficiencies may prevent its peripheral biological activation, we investigated the plasma level of zinc and of both active thymulin (Zn-FTS) and total zinc saturable thymulin (Zn-FTS + FTS) in 91 young patients affected by acute lymphoblastic leukemia (ALL) at various stages of the disease. It was discovered that the plasma zinc level was reduced at the onset and relapse, whereas in complete remission and in off- therapy it was in the normal range. Total zinc-saturable thymulin concentration did not change during the disease, whereas the active fraction was reduced at the onset and in relapse when compared with values observed in the other stages of the disease or in healthy controls. These data suggest that zinc plasma deficiency is present in ALL patients at the onset and during relapse, and that such a deficiency causes a decrease in the activity of thymulin despite a nearly normal production by the thymus. An impairment of peripheral immune efficiency in ALL patients is commonly found. The existence of positive correlations between zinc or active thymulin and peripheral immunological parameters (phytohemogglutinin [PHA] and concanavalin A [ConA]) at various stages of the disease suggests a link between derangement of peripheral immune function, thymic hormone activity, and zinc failure. These findings, considered together, suggest the possibility of a carefully controlled clinic trial with zinc in ALL patients at the onset and in relapse even in the light of in vitro ineffectiveness of physiological zinc or thymulin concentrations on the duplicative index of human lymphoblastoid cells.

UR - http://www.scopus.com/inward/record.url?scp=0028055046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028055046&partnerID=8YFLogxK

M3 - Article

VL - 83

SP - 749

EP - 757

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -